New York, October 5 /PRNewswire/ — Stock Preachers News Commentary — Wall Street ended the week with mixed results: the Nasdaq Composite closed at 27,190.86, up 1.19% on the day; the Dow Jones Industrial Average closed at 51,176.96, down 1.26% for the week. The S&P 500 rose 0.73% on the day to close at 7,722.72, but still posted a weekly decline; the Russell 2000 increased 0.94% to close at 2,832.90, though it remained in the red for the week. Gold, silver, and copper all rose, while oil declined; U.S. Treasury yields edged higher as markets continue to assess which signals to trust.
This week’s latest developments from actively traded companies include RTX (NYSE: RTX), Eli Lilly and Company (NYSE: LLY), International Business Machines Corporation (NYSE: IBM), Integra LifeSciences Holdings Corporation (NASDAQ: IART), and Trilogy Metals Inc. (NYSE American: TMQ).
The Dow Jones closed at 51,176.96 points, after reaching a weekly high of 51,780.50 and a low of 50,546.54, resulting in a 14-day RSI of 39.4 for this blue-chip index, indicating it is approaching oversold territory, despite a year-to-date gain of 6.48%. The S&P 500 closed at 7,722.72 points, with a 14-day RSI of 54.8, positioned between the 10-day simple moving average support at 7,707.82 and resistance at 7,771.48; the latter corresponds to the highs seen at the end of August and September.
The Nasdaq Composite closed at 27,190.86, near the support level associated with the early June 2026 high, with resistance above at the 52-week high of 27,353.68 set this week. Its 14-day RSI is 62.1, indicating strong momentum and a year-to-date gain of 16.99%. The Russell 2000 closed at 2,832.90, slightly above the mid-September low and the 10-day moving average at approximately 2,832.37, with a 14-day RSI of 39.6, reflecting a hesitant trend similar to the Dow.
Volatility has increased, with the VIX closing at 16.21, up 0.90 points on the day; the VXN, which favors the Nasdaq, declined to 21.20. In commodities, gold rose 0.64% to $4,189.10 per ounce; silver increased 3.76% to $62.24; WTI crude oil fell 0.58% to $90.58 per barrel. The 10-year U.S. Treasury yield rose 4 basis points on the day to 5.28%, for a total increase of 10 basis points this week.
The full report also breaks down the key support and resistance levels for each major index this week and looks ahead to factors that could move the market in the coming week.
Continue reading… For more news on RTX (NYSE: RTX), Eli Lilly and Company (NYSE: LLY), International Business Machines Corporation (NYSE: IBM), Integra LifeSciences Holdings Corporation (NASDAQ: IART), and Trilogy Metals Inc. (NYSE American: TMQ), visit the following link:
https://stockpreachers.com/articles/the-week-ahead-big-caps-hold-the-line-small-caps-hunt-for-footing/
Other industry developments and events this week include:
RTX (NYSE: RTX), through its Raytheon business, has been awarded a five-year contract, with two optional additional years, worth up to $24.4 billion for the Standard Missile-6 (SM-6) interceptor. This munition is capable of both offensive strike missions and missile defense operations for the U.S. Navy.
Raytheon President Phil Jasper said: “The multi-mission capability of the SM-6 is critical to our customers, and Raytheon is going all in to meet demand. We are continuously investing in operations and facilities to eliminate production constraints and increase output, ensuring the delivery of this vital capability that sailors rely on.”
The company stated that it has expanded its skilled workforce, strengthened collaboration with various stakeholders in the defense industrial base, and increased output through automated production. The SM-6 is described as the only weapon proven in combat capable of conducting air defense, anti-surface warfare, and ballistic missile defense.
Eli Lilly and Company (NYSE: LLY) has received FDA approval for an expanded indication of Lilly’s Jaypirca (pirtobrutinib) as a first-line treatment for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who are treatment-naïve and without known 17p deletion, based on the BRUIN CLL-313 trial.
At a median follow-up of 28 months in this trial, pirtobrutinib significantly improved progression-free survival compared to bendamustine plus rituximab, with a hazard ratio of 0.20. The overall response rate was 94% in the pirtobrutinib group and 81% in the control group.
“Based on BRUIN CLL-313, this additional approval for Jaypirca represents an important step forward in expanding its potential to benefit more patients who may benefit,” said Jacob Van Naarden, Executive Vice President and President of Oncology at Lilly.
International Business Machines Corporation (NYSE: IBM) — Hagens Berman Sobol Shapiro is investigating IBM after the company’s stock dropped 25% on July 14, 2026, following disclosures of Z mainframe performance shortcomings, wiping out more than $68 billion in market value.
CEO Arvind Krishna said, "Things have turned out worse than we anticipated due to Z performance and its associated software stack, particularly shortcomings in trade processing," and added, "Many large orders failed to execute."
“Some of the bad news came so suddenly that we are investigating whether and when the company possessed information indicating that large orders might not have been executed in a timely manner during IBM’s second quarter,” said Reed Kathrein, a partner at Hagens Berman leading the investigation.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) has lowered its full-year 2026 guidance following the July flood at its Cincinnati facility, now expecting third-quarter revenue of approximately $410 million to $412 million and adjusted earnings per share of $0.55 to $0.59.
The full-year revenue guidance has been lowered from $1.654 billion to $1.695 billion to $1.634 billion to $1.654 billion, and the adjusted EPS guidance has been reduced from $2.40 to $2.50 to $2.30 to $2.40. The company estimates that the flood reduced third-quarter revenue by approximately $7 million and expects an impact of $15 million to $20 million in the fourth quarter.
“Our third-quarter performance was impacted by the flood event at our Cincinnati facility in July,” said Stuart Essig, Chairman and CEO. “Although we have lowered our full-year 2026 revenue and adjusted EPS guidance, we still expect strong cash generation, including over $85 million in operating cash flow for the third quarter.”
Trilogy Metals Inc. (NYSE American: TMQ) disclosed a cash balance of $31.2 million and adjusted working capital of $30.3 million as of August 31, 2026; the company also completed a $35.6 million strategic equity investment from the U.S. Department of Defense on September 11, 2026.
The company reported a net profit of $200,000 for the third quarter, compared to a net loss of $1.7 million in the same period last year; for the first nine months, the net loss was $13.2 million, compared to a loss of $7.5 million in the same period last year.
"Q3 and the subsequent weeks have been transformative for Trilogy Metals," said President and CEO Tony Giardini. "With a clear permitting timeline, investment from the U.S. government, and a well-defined path to the Record of Decision, the Arctic project is now well-positioned to become a cornerstone of a secure, domestic copper supply chain."
Contact Information:
Media contact: [email protected]